AGM/EGMSep 18, 2026, 04:06 PM
Inhibitor Therapeutics Holds 2026 Annual Meeting; Directors Elected
AI Summary
Inhibitor Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders where directors were elected, the auditor was ratified, and the 2025 Share Incentive Plan was approved. Stockholders also provided advisory approval for executive compensation and indicated a preference for annual advisory votes on the matter. The elected directors will serve until the 2027 Annual Meeting.
Key Highlights
- Francis E. O’Donnell, Samuel J. Sears, Niraj Vasisht, Michelle Yanez, Michael Jerman and Ronald E. Osman were elected to the Board of Directors.
- Cherry Bekaert LLP was ratified as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2026.
- The 2025 Share Incentive Plan was approved by stockholders.
- Executive compensation received advisory approval with 96,854,767 votes for.
- Stockholders indicated a preference for annual advisory votes on executive compensation (22,443,829 votes).
Price Impact
More from INTI